home / stock / lgvn / lgvn articles
Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheim...
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a ce...
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company developing reg...
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Eme...
Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The t...
U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded up 0.26% t...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...